4SC AG - Domatinostat Program Update
4SC AG (4SC, FSE Prime Standard: VSC) today announced the results of a scheduled review of 4SC’s program for the clinica…
4SC AG (4SC, FSE Prime Standard: VSC) today announced the results of a scheduled review of 4SC’s program for the clinica…
First Patient Enrolled in TURANDOT Study Evaluating Domatinostat in the Neoadjuvant Setting in Urothelial Carcinoma Comb…
. - MERKLIN1 study progress update - EMERGE phase IIa clinical data presentation - DONIMI phase Ib clinical data presen…
* MERKLIN1: Trial in progress e-poster (ID 123) and oral presentation entitled "A phase II, open label, multicenter stud…
4SC today announced the initiation of a second clinical collaboration with the Netherlands Cancer Institute (NKI) on a p…
Prof. Dr. Jessica C. Hassel, Principle Investigator of the SENSITIZE study at the University Hospital Heidelberg, German…
4SC AG (4SC, FSE Prime Standard: VSC) will attend and present at the virtual 10th World Congress of Melanoma and 17th EA…
Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated…
4SC AG (4SC, FSE Prime Standard: VSC) today announced that a Trial in Progress poster entitled: 1153TiP - A phase II, op…
Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated…